Monogram [MGRM] vs Abbott Laboratories [ABT] Detailed Stock Comparison

Monogram Technologies Inc.

NASDAQ
Loading...

Abbott Laboratories

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Monogram Technologies Inc. wins in 5 metrics, Abbott Laboratories wins in 11 metrics, with 0 ties. Abbott Laboratories appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Monogram Technologies Inc. Abbott Laboratories Better
P/E Ratio (TTM) -13.04 25.97 Abbott Laboratories
Price-to-Book Ratio 25.10 3.09 Abbott Laboratories
Debt-to-Equity Ratio 3.44 26.79 Monogram Technologies Inc.
PEG Ratio -0.29 -1.41 Monogram Technologies Inc.
EV/EBITDA -16.52 13.74 Abbott Laboratories
Profit Margin (TTM) 0.00% 13.90% Abbott Laboratories
Operating Margin (TTM) 0.00% 16.50% Abbott Laboratories
EBITDA Margin (TTM) N/A 16.50% N/A
Return on Equity -228.82% 12.36% Abbott Laboratories
Return on Assets (TTM) -72.90% 7.52% Abbott Laboratories
Free Cash Flow (TTM) $-14.05M $7.40B Abbott Laboratories
Dividend Yield N/A 1.97% N/A
1-Year Return 157.51% -35.92% Monogram Technologies Inc.
Price-to-Sales Ratio (TTM) N/A 3.57 N/A
Enterprise Value $231.23M $166.96B Abbott Laboratories
EV/Revenue Ratio N/A 3.70 N/A
Revenue per Share (TTM) $0 $26 Abbott Laboratories
Earnings per Share (Diluted) $-0.54 $3.57 Abbott Laboratories
Beta (Stock Volatility) 0.69 0.78 Monogram Technologies Inc.
Short % of Float 0.49% 1.53% Monogram Technologies Inc.

Monogram Technologies Inc. vs Abbott Laboratories Stock Performance Analysis

Loading Price Chart...

MGRM
ABT

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Monogram Technologies Inc.0.00%1.69%4.35%81.82%151.05%138.10%
Abbott Laboratories-0.92%0.35%-0.65%-23.79%-31.15%-29.97%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Monogram Technologies Inc.157.51%-55.56%-55.56%-55.56%-55.56%-55.56%
Abbott Laboratories-35.92%-17.85%-21.68%118.48%249.25%313.73%

Performance & Financial Health Analysis: Monogram Technologies Inc. vs Abbott Laboratories

MetricMGRMABT
Market Information
Market Cap i$244.21M$160.70B
Market Cap CategoryMicro capLarge cap
10 Day Avg. Volume i262,12013,495,583
90 Day Avg. Volume i155,39312,934,461
Last Close$6.00$86.97
52 Week Range$1.92 - $6.13$81.97 - $139.06
% from 52W High-2.12%-37.46%
All-Time High$48.99 (May 15, 2023)$142.60 (Dec 27, 2021)
% from All-Time High-87.75%-39.01%
Growth Metrics
Quarterly Revenue GrowthN/A0.08%
Quarterly Earnings GrowthN/A-0.19%
Financial Health
Profit Margin (TTM) i0.00%0.14%
Operating Margin (TTM) i0.00%0.17%
Return on Equity (TTM) i-2.29%0.12%
Debt to Equity (MRQ) i3.4426.79
Cash & Liquidity
Book Value per Share (MRQ)$0.24$30.02
Cash per Share (MRQ)$0.32$5.14
Operating Cash Flow (TTM) i$-12,101,000$10.80B
Levered Free Cash Flow (TTM) i$-3,877,400$13.77B
Dividends
Last 12-Month Dividend Yield iN/A1.97%
Last 12-Month Dividend iN/A$2.40

Valuation & Enterprise Metrics Analysis: Monogram Technologies Inc. vs Abbott Laboratories

MetricMGRM (Oct 22, 2025)ABT (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-13.0425.97
Forward P/E i-12.5015.29
PEG Ratio i-0.29-1.41
Price to Sales (TTM) iN/A3.57
Price to Book (MRQ) i25.103.09
Market Capitalization
Market Capitalization i$244.21M$160.70B
Enterprise Value i$231.23M$166.96B
Enterprise Value Metrics
Enterprise to Revenue iN/A3.70
Enterprise to EBITDA i-16.5213.74
Risk & Other Metrics
Beta i0.690.78
Book Value per Share (MRQ) i$0.24$30.02

Financial Statements Comparison: Monogram Technologies Inc. vs Abbott Laboratories

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricMGRM (2024)ABT (2025)
Revenue/Sales i044.33B
Cost of Goods Sold iN/A19.32B
COGS % of Revenue i-43.6%
Gross Profit iN/A25.01B
Gross Margin i-56.4%
Research & Development i8.79M2.94B
Operating Income (EBIT) i-15.31M8.05B
Operating Margin i-18.2%
EBITDA i-14.88M12.03B
EBITDA Margin i-27.1%
Pre-Tax Income i-16.33M8.47B
Pre-Tax Income % of Revenue i-19.1%
Income Tax i01.94B
Income Tax % of Revenue i-4.4%
Net Income (Profit) i-16.33M6.52B
Profit Margin i-14.7%

Balance Sheet & Liquidity Metrics

MetricMGRM (2024)ABT (2025)
Cash & Equivalents i15.66M8.52B
Total Current Assets i16.28M26.00B
Total Current Assets % of Revenue i-58.6%
Total Current Liabilities i1.54M16.50B
Total Current Liabilities % of Revenue i-37.2%
Long-Term Debt i226,00010.83B
Long-Term Debt % of Revenue i-24.4%
Total Shareholders Equity i14.50M52.77B
Retained Earnings i-67.99M49.78B
Retained Earnings % of Revenue i-112.3%
Property, Plant & Equipment i1.32M17.57B

Cash Flow Statement Comparison

MetricMGRM (2024)ABT (2025)
Operating Cash Flow i-14.10M10.80B
Operating Cash Flow % of Revenue i-24.4%
Capital Expenditures i-84,000-2.17B
Free Cash Flow i-14.05M7.40B
FCF Margin i-16.7%
Debt Repayment iN/A-1.50B
Common Stock Repurchase i-200,000-893.00M

Short Interest & Institutional Ownership Analysis

MetricMGRMABT
Shares Short i161,43123.83M
Short Ratio i1.661.93
Short % of Float i0.49%1.53%
Shares Outstanding i36.09M1.74B
Float Shares i30.58M1.73B
% Held by Insiders i54.55%0.54%
% Held by Institutions i4.97%82.23%
% Held by Public i40.48%17.23%

Dividend Analysis & Yield Comparison: Monogram Technologies Inc. vs Abbott Laboratories

MetricMGRMABT
Last 12-Month Dividend iN/A$2.40
Last 12-Month Dividend Yield iN/A1.97%
3-Year Avg Annual Dividend iN/A$2.24
3-Year Avg Dividend Yield iN/A0.50%
3-Year Total Dividends iN/A$6.72
Ex-Dividend DateN/AJan 15, 2026